Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
Imiquimod
55
CHF
CHF 55.00
In stock
AG-CR1-3569-M100100 mgCHF 55.00
AG-CR1-3569-M250250 mgCHF 110.00
| Product Details | |
|---|---|
| Synonyms | 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline; S26308; R-837 |
| Product Type | Chemical |
| Properties | |
| Formula |
C14H16N4 |
| MW | 240.3 |
| CAS | 99011-02-6 |
| Purity Chemicals | ≥98% |
| Appearance | White to off-white powder. |
| Solubility | Soluble in DMSO or dimethylformamide. Insoluble in ethanol. Slightly soluble in water. |
| Identity | Determined by IR. |
| InChi Key | DOUYETYNHWVLEO-UHFFFAOYSA-N |
| Smiles | CC(C)CN1C=NC2=C1C1=CC=CC=C1N=C2N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | After reconstitution, prepare aliquots and store at -20°C. |
| Use/Stability |
Stable for at least 2 years after receipt when stored at -20°C. Stock solutions are stable for at least 3 months when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Immune response modulator [1, 2].
- Anti-inflammatory [3, 5].
- TLR7 agonist [3, 5].
- Stimulates proinflammatory cytokine production interferon-α (IFN-α), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) and activates NF-κB [3, 5].
- Caspase-3 activator that directly induces procaspase-3 cleavage [4].
- Anti-cancer compound [4, 9].
- Apoptosis inducer [4, 9].
- Antiproliferative, independent of immune system activation or function.
- Antiviral [10] and anti-angiogenic [6, 7, 8].
- Approved treatment for external genital warts (Condyloma acuminata) caused by human papillomavirus infection [10].
Product References
- Imiquimod applied topically: a novel immune response modifier and new class of drug: R.L. Miller, et al.; Int. J. Immunopharmacol. 21, 1 (1999)
- A review of the applications of imiquimod: a novel immune response modifier: T.A. Syed, et al.; Exp. Opin. Pharmacother. 2, 877 (2001)
- Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway: H. Hemmi, et al.; Nat. Immunol. 3, 196 (2002)
- Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod: M. Schon, et al.; J. Natl. Cancer Inst. 95, 1138 (2003)
- Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7: J. Lee, et al.; PNAS 100, 6646 (2003)
- In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases: C. Hesling, et al.; Br. J. Dermatol. 150, 761 (2004)
- Imiquimod as an antiangiogenic agent: V.W. Li, et al.; J. Drugs Dermatol. 4, 708 (2005)
- Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis: S. Majewski, et al.; Int. J. Dermatol. 44, 14 (2005)
- The antitumoral mode of action of imiquimod and other imidazoquinolines: M. Schon & M.P. Schon; Curr. Med. Chem. 14, 681 (2007)
- The pharmacology of endosomal TLR agonists in viral disease: D.R. Averett, et al.; Biochem. Soc. Trans. 35, 1468 (2007)
- TLR7 agonists display potent antiviral effects against norovirus infection via innate stimulation: D.E. Tuipulotu, et al.; Antimicrob. Agents Chemother., 62, e02417 (2018)
- Procyanidin B2 3,3′′-di-O-gallate ameliorates imiquimod-induced skin inflammation by suppressing TLR7 signaling through the inhibition of endosomal acidification in dendritic cells: T. Sawa, et al.; Int. Immunopharmacol. 121, 110444 (2023)
Related Products
